Indian drug firm Dr Reddy’s Laboratories has started dosing in a randomised, double-blind, placebo-controlled and parallel-group Phase II trial of DRL-17822 in patients suffering from type II dyslipidemia.
DRL-17822, a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein, for the treatment and prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.
Go deeper with GlobalData
The study aims to evaluate the safety and efficacy of DRL-17822 in patients with type-II dyslipidemia.
In the study, three doses (50mg, 150mg and 300mg) of DRL-17822 given once daily for four weeks will be investigated.
Three Phase I human studies with DRL-17822 have already been conducted in Europe, and showed the drug to be safe and well tolerated.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
